Inanovate
Sioux Falls, US · Delaware corporation
Founders & leadership
DU
David UreExecutive
JE
James E OuryExecutive
Board
BC
Blaine CrissmanBoard director
KP
Katie PohlsonBoard director
PD
Peter D. LosBoard director
DA
David ArslanianBoard director
GH
George HolmesBoard director
MH
Michael H. GoldsteinBoard Member
RM
Randall MarfinBoard Member
Reported raises · per SEC filings
Form D private placements$13M disclosed across 10 rounds · 2015–2025
▶$808KraisedJul 2025 · 2 investors · BiotechnologyRule 506(b)
▶$808KraisedJul 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David UreExecutive Officer, Director
- Peter D LosDirector
- George HolmesDirector
- Blaine CrissmanDirector
- David ArslanianDirector
- James E OuryExecutive Officer
- Katie PohlsonDirector
- Offering amount
- $808K
- Amount sold
- $808K
- Minimum investment
- $10K
- Proceeds to insiders
- $50K
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$900KraisedNov 2024 · 6 investors · BiotechnologyRule 506(b)
▶$900KraisedNov 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Blaine CrissmanDirector
- Katie PohlsonDirector
- David UreExecutive Officer, Director
- Peter D LosDirector
- James E OuryExecutive Officer
- David ArslanianDirector
- George HolmesDirector
- Offering amount
- $900K
- Amount sold
- $900K
- Minimum investment
- $10K
- Proceeds to insiders
- $100K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJun 2024 · 4 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJun 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katie PohlsonDirector
- James E OuryExecutive Officer
- Blaine CrissmanDirector
- David ArslanianDirector
- David UreExecutive Officer, Director
- George HolmesDirector
- Peter D LosDirector
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- Proceeds to insiders
- $300K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedDec 2023 · 3 investors · BiotechnologyRule 506(b)
▶$1.5MraisedDec 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ArslanianDirector
- Blaine CrissmanDirector
- Katie PohlsonDirector
- George HolmesDirector
- Peter D LosDirector
- James E OuryExecutive Officer
- David UreExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.5M
- Minimum investment
- $10K
- Proceeds to insiders
- $300K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedOct 2022 · 7 investors · BiotechnologyRule 506(b)
▶$2.4MraisedOct 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kent LehrDirector
- David UreExecutive Officer
- James E OuryExecutive Officer
- Kamran TahamtanzadeDirector
- George HolmesDirector
- David ArslanianDirector
- Peter D LosDirector
- Blaine CrissmanDirector
- Offering amount
- $3M
- Amount sold
- $2.4M
- Minimum investment
- $10K
- Proceeds to insiders
- $300K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedFeb 2022 · 11 investors · BiotechnologyRule 506(b)
▶$1.8MraisedFeb 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter D LosDirector
- George HolmesDirector
- Michael GoldsteinDirector
- Blaine CrissmanDirector
- David UreExecutive Officer
- David ArslanianDirector
- James E OuryDirector
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Minimum investment
- $10K
- Proceeds to insiders
- $300K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$455.3KraisedJul 2020 · 6 investors · BiotechnologyRule 506(b)
▶$455.3KraisedJul 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David UreExecutive Officer
- Michael GoldsteinDirector
- Peter D LosDirector
- Blaine CrissmanDirector
- George HolmesDirector
- David ArslanianDirector
- James E OuryDirector
- Offering amount
- $455.3K
- Amount sold
- $455.3K
- Minimum investment
- $10K
- Proceeds to insiders
- $25K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$439.2KraisedNov 2019 · 3 investors · BiotechnologyRule 506(b)
▶$439.2KraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David UreExecutive Officer
- James E OuryDirector
- Peter D LosDirector
- George HolmesDirector
- Michael GoldsteinDirector
- David ArslanianDirector
- Blaine CrissmanDirector
- Offering amount
- $439.2K
- Amount sold
- $439.2K
- Minimum investment
- $10K
- Proceeds to insiders
- $25K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Inanovate for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2021 | $255.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $199.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has Inanovate raised?
- Inanovate has disclosed $13M raised across 10 rounds.
- Where is Inanovate headquartered?
- Inanovate is headquartered in Sioux Falls, US.